|
|
Post by sayhey24 on May 30, 2024 11:22:47 GMT -5
Al perused it and was very excited about it. However, as Al said there are 3 things you need to grow a business; money; money; and MORE Money. He had to set priorities and afrezza was #1. While thats the end of that story we are opening another. Iconovo thinks its a pretty great idea. I have made them aware of Mannkind's work 15years ago and I think they may have a winner. We will see. Look - I tried with MNKD and I will continue to be a broken record but it is what it is at this time. Mike decided to buy V-Go and now announced something with PLUM which has plummeted our pps. I have not yet seen any announcement on gestational diabetes so I guess Mike is still talking on this. I have also not seen any movement on the afrezza/glp1 study for T2s. I did however see how we can now use iSperse for insulin. I guess this is to replace technosphere but I have yet to figure that out but I am sure Mike has another plan. They have already tested the iSperse dry powder with insulin and apparently had good results. The iSperse utilizes cationic salt formulations. The iSperse is just a proprietary dry powder formulations just like our FDKP formulations are. They load molecules onto it like we couple molecules onto FDKP. It can be used in various modalities, and works well with high resistance inhalers, which is exactly what MannKind has. Further, iSperse can be used for formulating drug combinations, I’m not sure how feasible that is with Technosphere. It also has a strong safety profile considering its formulations are comprised of GRAS salts. www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A2761Why would we spend a penny on putting insulin on iSperse when nothing beats afrezza? Now, if iSperse does work well with insulin and a BP was looking at it and Mike locked it up, then Mike just scored a Touchdown. |
|
|
|
Post by stockwhisperer on May 30, 2024 11:35:44 GMT -5
Touchdown PLUS… I believe MNKD knows what they are doing. Certainly more than any of us. No doubt, plenty of thought went into this deal - imo, no reason it won’t be a great one. MC said, “We have formulated two FDA-approved products utilizing our proven Technosphere® dry powder technology, and this agreement affords us access to another option for future development opportunities.”
“Our Technosphere technology, which is a unique carrier-based, dry powder inhalation platform used in tandem with our proprietary inhaler, provides deep and effective penetration of lung tissue that is well suited for many active ingredients,” said Dr. Burkhard Blank, Executive Vice President, Research & Development and Chief Medical Officer of MannKind Corporation. “However, for some drug candidates, such as Clofazimine, that may require a significantly higher drug payload, the iSPERSE formulation technology may be better suited for developing viable powders.”
The royalty-free licensing structure will allow MannKind to have exclusive use of the iSPERSE technology for clofazimine, NTM, and insulin, and non-exclusive use for endocrine diseases and interstitial lung diseases (ILD) including idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PFF) and other related lung diseases. In exchange, Pulmatrix will receive a royalty-free, exclusive license to MannKind’s single-use Cricket inhalation device for inhaled delivery of DHE in any formulation and non-exclusive use for neurological diseases.
|
|
|
|
Post by Thundersnow on May 30, 2024 11:39:39 GMT -5
I remember Al saying a TS GLP-1 works too fast and is not worth developing. Al was saying NATIVE GLP1 was not a viable drug because it worked too fast. We are not talking about native GLP1. We are talking about an analog like Saxenda which will be coming off patent soon. We should be able to quickly do a pilot and then go right to P2 since both TS and Saxenda are approved. All I am talking about is a pilot and lets see if it works. When I first brought this up Mike told me I was wrong about the GLP1 work. Then he found it and submitted the patent. I think $5M on the pilot is money better spend than any time with PLUM. First we paid the bill for the V-Go reps and then finally let them go. Now we are paying for another staff, who is foing God knows what. I think Mike is looking at the GLP-1 landscape. Many players are moving into this space quickly. |
|
|
|
Post by Thundersnow on May 30, 2024 11:41:16 GMT -5
That's a non issue. PULM has no money to develop anymore drugs.  |
|
|
|
Post by stockwhisperer on May 30, 2024 12:00:58 GMT -5
Wow, so much energy from the get go on what might go wrong with a deal that barely has its foot out the door and hasn’t even been signed yet. Would be great to see the energy placed on all that might go right from shareholders that believe in their investment and want it to succeed.
|
|
|
|
Post by harryx1 on May 30, 2024 12:01:09 GMT -5
They have already tested the iSperse dry powder with insulin and apparently had good results. The iSperse utilizes cationic salt formulations. The iSperse is just a proprietary dry powder formulations just like our FDKP formulations are. They load molecules onto it like we couple molecules onto FDKP. It can be used in various modalities, and works well with high resistance inhalers, which is exactly what MannKind has. Further, iSperse can be used for formulating drug combinations, I’m not sure how feasible that is with Technosphere. It also has a strong safety profile considering its formulations are comprised of GRAS salts. www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A2761Technosphere can handle drug combinations (i.e. can have a mixture of multiple molecules) however iSperse may be able to handle larger molecules that Technosphere can't. I think it's a great move as iSperse fits right into MNKD's wheelhouse and could potentially eliminate a competitor. Plus down the road if they are thinking of acquiring the whole company PUR1900 fits into the lung division (and could be targeted to Cystic Fibrosis as well) if they decide to revive it. |
|
|
|
Post by sayhey24 on May 30, 2024 12:41:24 GMT -5
Al was saying NATIVE GLP1 was not a viable drug because it worked too fast. We are not talking about native GLP1. We are talking about an analog like Saxenda which will be coming off patent soon. We should be able to quickly do a pilot and then go right to P2 since both TS and Saxenda are approved. All I am talking about is a pilot and lets see if it works. When I first brought this up Mike told me I was wrong about the GLP1 work. Then he found it and submitted the patent. I think $5M on the pilot is money better spend than any time with PLUM. First we paid the bill for the V-Go reps and then finally let them go. Now we are paying for another staff, who is foing God knows what. I think Mike is looking at the GLP-1 landscape. Many players are moving into this space quickly. Its $100B+ market and we have both Technosphere know how and Saxenda. While many players may be moving into the space we should have been there 2 years ago with Victoza. With Mike and team they seem to talk and think about things like GLP1s and Gestational diabetes and then loose focus on things like V-Go and PLUM. Even is we got 1% of $100B+ thats a home run and cost little to develop. I hope you are right but IMO just the thought of BP scares Mike. He would rather find a PLUM in the trash can than sit at the lunchroom table with the big boys. I hope I am wrong but so far Mike has proved me right. Its been 2 years since I asked him about our GLP1 plans for weight loss and he went off one why it is hard to compete with GLP1s in the T2 space. |
|
|
|
Post by awesomo on May 30, 2024 14:01:54 GMT -5
Wow, so much energy from the get go on what might go wrong with a deal that barely has its foot out the door and hasn’t even been signed yet. Would be great to see the energy placed on all that might go right from shareholders that believe in their investment and want it to succeed. These types of deals have never amounted to anything for MannKind, so there's a reason for the skepticism. |
|
|
|
Post by cretin11 on May 30, 2024 14:25:35 GMT -5
Wow, so much energy from the get go on what might go wrong with a deal that barely has its foot out the door and hasn’t even been signed yet. Would be great to see the energy placed on all that might go right from shareholders that believe in their investment and want it to succeed. These types of deals have never amounted to anything for MannKind, so there's a reason for the skepticism. That's a fair point. Moreover, for those of us who've been on PB here for a decade or longer, we've seen the vast majority of posts be about "all that might go right" - yet the reality has been 90% of those things have not panned out the way our optimistic posts have predicted. awesomo and sayhey make accurate observations about our track record with these things. It's fine to want the rose colored perspective, but in my personal opinion it's more valuable to have accuracy and an objective take on things rather than constant bullish spin. It's true now as it always has been: if we perform our share price will reflect it, the market isn't playing favorites it is objectively evaluating our decisionmaking, execution and results. |
|
|
|
Post by mymann on May 30, 2024 14:31:28 GMT -5
It's like buying a second hand lawn mower at a rummage sell. Don't spend too much money or none and make yourself look good owning two lawn mower to cut the same yard. Board must of liked it to allow Mike to do the deal.
|
|
|
|
Post by stella on May 30, 2024 14:48:02 GMT -5
It's like buying a second hand lawn mower at a rummage sell. Don't spend too much money or none and make yourself look good owning two lawn mower to cut the same yard. Board must of liked it to allow Mike to do the deal. Yeah, that must be what's going on here. Another insightful, value-added post, mymann. Kudos. |
|
|
|
Post by mytakeonit on May 30, 2024 15:01:01 GMT -5
Or instead of buying 2 lawn mowers ... buy astro turf.
GO MNKD !!!
|
|
|
|
Post by RainbowUnicorn on May 30, 2024 15:03:06 GMT -5
Wow, so much energy from the get go on what might go wrong with a deal that barely has its foot out the door and hasn’t even been signed yet. Would be great to see the energy placed on all that might go right from shareholders that believe in their investment and want it to succeed. These types of deals have never amounted to anything for MannKind, so there's a reason for the skepticism. "I have failed again and again throughout my life. That's why I've been successful". Michael Jordan |
|
|
|
Post by mango on May 30, 2024 15:17:19 GMT -5
Wow, so much energy from the get go on what might go wrong with a deal that barely has its foot out the door and hasn’t even been signed yet. Would be great to see the energy placed on all that might go right from shareholders that believe in their investment and want it to succeed. These types of deals have never amounted to anything for MannKind, so there's a reason for the skepticism. Tolero, Rose Pharma, Torry Pines, Receptor, Damon Dash, Charles Mattocks, One Drop, Immix, NRx, TechnoVax, Mintaka Foundation, Sun Pharma, and United. Granted, this is not a collaboration and more of a “trade,” and a good one at that, at least on paper until we know more about MannKind’s potential future plans with iSperse. Mike is responsible for 5 of the failed partnerships/collabs in the list above. However, he’s also responsible for one successful one which makes up for all the failed ones (United Therapeutics). FYI, Receptor pulled their clinical trials with Technosphere due to lack of enrollment. Matthew Pfieffer was responsible for Receptor. |
|
|
|
Post by stockwhisperer on May 30, 2024 15:37:39 GMT -5
Cretin, There’s no accuracy about it. It’s just negativity on top of negativity. Nothing but opinions of mostly doom & gloom based on zero reality and that’s my take on it. Why anyone would hold a stock if they feel this way about the company, the CEO, etc., despite the complete turnaround and all the facts of how well MNKD is doing in the here and now, is beyond me. Carry on.
|
|
